FANDOM


THURSDAY October 18
PLENARY: 09:00 - 10:30

OPENING & WELCOME

Laurent Miéville, President ASTP, Opening

Fabio Gava, Regional Minister for Economic and Institutional Policies, Gianpietro Marchiori, CEO of VEGA, Fabrizio Bettiol, Vice-President Uninsutria Venezia, Welcome
Leo Roodhart, Strategic Innovation, Shell International, the Netherlands

PARALLEL : 11:00 - 12:30

INTRO TRACK:
DRAFTING THE AGREEMENTS

The DNA of CDA’s & MTA’s

DOING THE TRANSACTION:
REDUCING KNOWLEDGE TO PRACTICE
Negotiating the deal

STRATEGIES, NEEDS AND PRACTICES

OF INDUSTRY


Medical technologies

Mark Anderson, Anderson & co, United Kingdom
Allen Norris, Vice President, Head Group IP, UCB Pharma, Belgium
A lot of research collaborations find their origin in exploratory discussions and exchanges of material. How to get it right from the start and make sure that your information or material is not misused … or that you are not unreasonably bound because you received information or material from your counterparty.

Herman Verrelst, Director European Operations, Norkom Technologies, Belgium
Erwin Blomsma, Director Strategic Development, Avantium Technologies, the Netherlands
Even when you have a groundbreaking technology to offer, it still is not always easy to come to a balanced deal. This session discusses several factors that can lead to success or failure when negotiating and (hopefully) closing a technology deal, and navigates you through negotiation tactics and strategies.

Frank Bistervels, Senior Director Technology Licensing, Philips Intellectual Property & Standards, the Netherlands
Federico Bilotti, Director Franchise Department Johnson & Johnson, Italy
What are the issues that are really important for industry, and how do these issues influence their interaction with research institutions? How do they identify and acquire technology? What are their main business drivers and which elements determine their long and short term strategy? What do they expect from us? Decision makers from within five different sectors guide us through

PARALLEL: 14:00 - 15:15

INTRO TRACK:
DRAFTING THE AGREEMENTS
Defining the relationship

DOING THE TRANSACTION:
REDUCING KNOWLEDGE TO PRACTICE
Pricing your offering

STRATEGIES, NEEDS AND PRACTICES OF INDUSTRY
Telecommunications

Mark Anderson, Anderson & co, United Kingdom
Alan Payne, Operations Manager & Photographic Projects Manager, Kodak European Research, United Kingdom
Research relationships with industry can be complex involving a mixture of ongoing collaboration, consultancy, material exchange and licensing of background and foreground IP. Researchers structure these relationships and then expect us (as TT professionals) to translate their requirements (overnight) into a coherent contract. In this first of three sessions on research agreements we use an actual R&D case study to analyze our role in translating academic requirement into a structured legal agreement

Kevin Cullen, Director of Research and Enterprise, University of Glasgow, United Kingdom
Alan Lamont, Director Science and Technology Alliances, Astra Zeneca, United Kingdom
How do you know how much to ask for a technology? The (e)valuation process is a complex task, involving issues such as commercial analysis, financial analysis, profile of the inventor, stage of the development, and many more elements. Is it possible to develop "the roadmap to a correct pricing"?

Keith Everard, Strategic University Research Program Manager, British Telecom, United Kingdom
François Jamet, Director Intellectual Property & Licensing, France Telecom, France
The Telecom industry has undergone huge changes in the last few years. National monopolies are no more, physical networks have become commodities and the business model is being challenged by VOIP. In this new age what do the major telecoms companies need from the research base?

PARALLEL : 15:45 - 17:00

INTRO TRACK:
DRAFTING THE AGREEMENTS
Common pitfalls

DOING THE TRANSACTION:
REDUCING KNOWLEDGE TO PRACTICE
Tracking down inventions

STRATEGIES, NEEDS AND PRACTICES OF INDUSTRY
Healthcare / Consumer products

Mark Anderson, Anderson & co, United Kingdom
Michel Benard,, Director Technology Programs, HP University Relations, Switzerland
Research collaborations are the cornerstone of the activities of most TTO's, so mastering the art of drafting the agreements that set out the rules for these collaborations is of prime importance. Experts guide you through the most important clauses, the do’s & don’ts and provide you with practical tips for a perfect contract

Cecile Tharaud, Head of technology Transfer, INSERM, France
Alan Payne, Operations Manager & Photographic Projects Manager, Kodak European Research, United Kingdom
We all are focused on bringing technology to the market. But are we sure that we don’t miss too much opportunities that never reach our offices? How do big corporations scout for technology opportunities within their own organization? Can we learn from them?

Alan Lamont, Director, Science and Technology Alliances, AstraZeneca, United Kingdom
Robert Pinnock, Director, Academic Scientific Liaison Europe, Merck
The Healthcare sector is facing major challenges - development and regulatory costs are rising at a time when product pipelines are diminishing. They are seeking new technologies to achieve greater speed and efficiency and early screening – and alliances to fill pipelines. Universities are as important as ever but the way in which we engage will change.

FRIDAY October 19th
PLENARY: 09:00 - 10:30

OPENING SESSION

Ron Botham, Training and Employment Research Unit (TERU), University of Glasgow, United Kingdom,The economic impact of TTO’s - aligning our business models.

PARALLEL : 11:00 - 12:30

INTRO TRACK:
DRAFTING THE AGREEMENTS
Standard Agreements – Fool’s Gold?

DOING THE TRANSACTION:
REDUCING KNOWLEDGE TO PRACTICE
Joint ownership of IP

STRATEGIES, NEEDS AND PRACTICES OF INDUSTRY
Information technology

Jeff Skinner, Director Corporate Alliances, UCL, United Kingdom
Ursula Haufe, Managing Director, Ipal Berlin, Germany
Johan Schlüter,, Chairman, Working Group Danish Industry Association, Denmark
Everybody in Germany is talking about the "Berliner" and "Hamburger" Verträge (agreements) which are standard agreements for collaboration and contract research between industry and academia.

William Bird, Founding Partner, Bird Goën & co, Belgium
Allen Norris, Vice President, Head Group IP, UCB Pharma, Belgium
Kevin Cullen, Director of Research and Enterprise, University of Glasgow, United Kingdom
Some love it, some hate it. Is it a feasible option or do we better try to avoid joint ownership of intellectual property at all times? What are the modalities that can make joint ownership work?

Michel Benard, Director Technology Programs, HP University Relations, Switzerland
Charles Irving, Founder, Pond Ventures, United Kingdom
Darko Piscevic,Director Account & Marketing Strategy, Infineon Technologies Communication, Germany
The ICT ’industry’ moves very fast and is structured in such a way that makes it difficult to ‘digest’ university technologies. Moreover, IP is harder to protect since single patents offer little protection. Added to that, ‘killer applications’ are far from obvious. How then are we supposed to engage with the major ICT users?

PARALLEL : 14:00 - 15:15

INTRO TRACK:
DRAFTING THE AGREEMENTS
Clinical Trial Agreements

DOING THE TRANSACTION:
REDUCING KNOWLEDGE TO PRACTICE
Case study on industry collaboration

STRATEGIES, NEEDS AND PRACTICES OF INDUSTRY
Food and functional food industry

Riikka Roman,, Senior Legal Counsel Research and Industrial Services, University of Turku, Finland
Franziska Weise,, Unitectra, Office of Technology Transfer Universities Bern & Zürich, Switzerland
There are many reasons why clinical trial agreements (CTA) form a very specific species of contract, with the fact that human beings are the subject of the research as one of the most important reasons. This entails specific requirements for CTA's, such as informed consent/use of patient material, the EU Clinical Trial Directive, liability clauses, etc

Jan Delcour, Professor Food Science and Microbiology, KU Leuven, Belgium
The real work has to be done by the researcher himself! A personal testimony from a professor who successfully built up his research through consistently collaborating with industry, including licensing deals. What are the major hurdles and challenges he has experienced, and how does he see the role of the TTO?

Fillip Arnaut, Group LT Research Director, Puratos, Belgium
Ariane Andres, Head External Alliance, Nestlé Research Centre, Switzerland
For a long time food had to be tasty, safe and reasonably priced. These days a major shift is ongoing towards functional food. How do evolutions towards convenience, shelf life and pre-biotics influence our interaction with industry? Is a new collaboration model required for the food of the future?

PLENARY: 15:30 - 16:30

FINAL SESSION : How good relationships are built and maintained

Ron Botham, Training and Employment Research Unit (TERU), University of Glasgow, United Kingdom
Michel Benard, Director Technology Programs, HP University Relations, Switzerland
Jeff Skinner, Director Corporate Alliances, UCL, United Kingdom
Jan Delcour,, Professor Food Science and Microbiology, KU Leuven, Belgium
In this age of ‘Open Innovation’ businesses need to find reliable R&D partners – and many would like to build such links with universities. Likewise, universities are increasingly driven to demonstrate economic impact. This should be a marriage made in heaven but we all know that there are substantial barriers to effective engagement and exchange. What are the main obstacles and what can we do to build & foster good working relationships between ‘our’ academics and their counterparts in businesses. Should our efforts be focused primarily on the contractual arrangements or is problem more one of building mutual trust, confidence and knowledge of each other’s capabilities and needs?